Indeed, the three identified studies addressing lower TMB in IDH‐mutant gliomas suggest that there must be a mechanism other than G‐CIMP affecting the mutational rate in IDH‐mutant glioma. This evidence concerns the gene IDH1 and central nervous system cancer.